Michael Martin

Michael Martin is President, Chief Executive Officer & Director at Plexium, Inc. since 2024.
Dr. Martin is Director at BioMotiv LLC, Bioniz Therapeutics, Inc., OrphoMed, Inc., Ambys Medicines, Inc., and Abintus Bio, Inc. Former roles include Director-Pharmaceutical Properties Assessment at TargeGen, Inc., Independent Director at Avidity Biosciences, Inc. from 2016 to 2021, Director-Preclinical Development at Intellikine LLC, Director at Univercells SA and Palleon Pharmaceuticals, Inc., Principal at Arena Pharmaceuticals, Inc. and Monsanto Co., Member-Global Licensing & Business Development at Takeda Pharmaceutical Co., Ltd. from 2012 to 2015, and Principal at G.D.
Searle LLC.
Education includes undergraduate and graduate degrees from St. Louis University and a doctorate from the University of Illinois.